Moderna stock up 85% after its latest cancer drug trials showed very positive results https://t.co/KGZpDGUFGr ...

wowNone (@None):MERCK $MRK AND MODERNA $MRNA JUST HIT THE FIRST POSITIVE PHASE 3 RESULT EVER FOR A PERSONALIZED CANCER VACCINETheir Phase 3 INTerpath-001 trial found that "intismeran autogene, an mRNA therapy custom-built from each patient's own tumor mutations, combined with Merck's KEYTRUDA, https://t.co/9mMcrACjmZ ...

Moderna Shares Skyrocket 85% Toward Best Day Ever—On Success Of Cancer Drug Trialhttps://t.co/teGZUvCViQ https://t.co/C9neTnLIHs ...

Moderna and Merck said their personalized cancer vaccine helped cut the recurrence of melanoma in a large, late-stage trial https://t.co/AHcJjZjvuq ...

Shares of Madna and Merc are surging this morning and that is uh no exaggeration. Check it out. Shares of Merc right now up by about seven and three/4ers percent.Of course, before those moves, this was a company with a $333 billion market cap. So that is substantial when you're talking numbers. And then check out shares of Madna.They are up 63%, a gain of close to $40 right now. Uh the stock is now trading at $102. By the way, before that move, that was a stock with about a $25 billion valuation.So you're p ...

Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said, sending shares of the vaccine maker up 60% in premarket ​trading. https://t.co/AbE55DcOOj https://t.co/qP9KEh1ECg ...

Legal and Regulatory Risks - Meta Platforms faces a landmark trial brought by California and other states seeking financial penalties and policy changes over alleged social media addiction and youth mental health harms [1][2] - The US Securities and Exchange Commission proposed new rules to clarify digital asset regulation and streamline capital formation for crypto entrepreneurs [5] Market Trends and Macroeconomics - Global government bond yields surged to their highest levels since 2007, raising financing costs and pressuring equity markets worldwide [2][4][5] - Global equity markets experienced volatility and risk-off sentiment, led by heavy selling in AI-related shares, particularly in Asian markets such as South Korea [6][9] - Oil prices climbed due to the expiration of the US-Iran ceasefire and renewed geopolitical risks raising concerns over global supply disruptions [9] Corporate Performance and Industry Dynamics - Unitry Robotics debuted on the Shanghai Star Market, soaring 460% on its first day of trading and closing with a market capitalization near 50 billion USD, becoming China's first listed humanoid robot maker [3] - Target delivered a strong earnings beat for the second quarter of fiscal year 2026 and raised its outlook driven by sales rebounds and a large tariff refund [4] - Moderna and Merck announced that their personalized mRNA cancer vaccine met key endpoints in a late-stage melanoma trial, sending Moderna shares up 50% in pre-market trading [7] - American Airlines announced plans to add 4,000 seatback entertainment screens across more than 800 aircraft and expand premium seating to attract higher-spending travelers [8]